Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma

Review

(2002) Views  (510) Full article downloads

Authors: Michael J Burdick, Roger M Macklis

Published Date August 2009 Volume 2009:2 Pages 229 - 242

DOI: http://dx.doi.org/10.2147/OTT.S4456

Michael J Burdick, Roger M Macklis

Department of Radiation Oncology, Taussig Cancer Center and Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA

Abstract: Targeted radioimmunotherapy in non-Hodgkin’s B-cell lymphoma (NHL) offers an efficacious therapy and minimal toxicity compared to conventional chemotherapy. Iodine 131 tositumomab (¹³¹I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated to ¹³¹I, a radioactive β and γ emitter. While initially approved for use in relapsed, refractory, or transformed low grade B-cell NHL, investigational uses with promising results include autologous stem cell transplant, intermediate grade NHL, and the frontline management of indolent NHL. This review summarizes the ¹³¹I-TST literature on mechanism of action, treatment indications, treatment delivery, efficacy, investigational uses, and future prospects.

Keywords: tositumomab, radioimmunotherapy, non-Hodgkin’s lymphoma, Bexxar